This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Osteoarthritis  • Diagnosis  • Alert me on articles by topic

Tracy Hampton, PhD

JAMA. 2004;291:1951.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

A new public-private partnership between the National Institutes of Health and the pharmaceutical industry is establishing a program to hasten discovery of biological markers for osteoarthritis.

Biological specimens, images, and clinical data will be collected from men and women aged 45 years or older at risk for developing osteoarthritis or those with early stages of the disease. Scientists hope to identify new biological markers that indicate changes in bone or cartilage, which may help in the diagnosis and treatment of osteoarthritis.

Four clinical centers involving six institutions will each enroll and monitor 1250 adults for 5 years: University of Maryland School of Medicine and the Johns Hopkins University, both in Baltimore; the Ohio State University Medical Center in Columbus; University of Pittsburgh in Pittsburgh, Pa; and Memorial Hospital of Rhode Island and Brown University, both in Providence. Data will be collected annually.

Background information about the study . . . [Full Text of this Article]